Obesity and body weight control

January 26, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
January 18, 2018

Vitamin-based therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture (PMSF) encompassing Pyridoxamine (PM) and Sildenafil (SF) decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 18/January/2017, 11.54 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]
January 17, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Melatonin, a hormone that regulates sleep and wakefulness, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 17/January/2018, 10.10 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
January 15, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Fluoxetine[Trade name: Prozac and Sarafem], an antidepressant,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 16/January/2018, 4.55 am

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]